Laboratory solutions provider Thermo Fisher Scientific has introduced the Invitrogen EVOS S1000 Spatial Imaging System to simplify the tissue imaging process.
The Invitrogen EVOS S1000 enables researchers to generate data and enter the spatial tissue proteomics sector. It also lowers entry barriers for them.
This advanced system overcomes the limitations of traditional fluorescent microscopy technologies.
It allows researchers to create multiplexed images from multiple samples within a few hours.
The Spatial Imaging System, part of Thermo Fisher Scientific’s Cell Imaging Microscopes And Systems line, uses advanced spectral technology to capture up to nine targets simultaneously.
The laboratory solutions provider said that this reduces the need for multiple imaging rounds and preserves tissue integrity.
It also features intuitive software, allowing researchers to enhance tissue sample analysis, while reducing processing time, image collection, navigation, and data retrieval.
Additionally, the device streamlines image acquisition with automated laser and software-based autofocus routines.
Thermo Fisher Scientific vice president and flow and imaging technologies general manager Trisha Dowling said: “Understanding tissue structure and function is crucial for developing new treatments for solid tumours and neurodegenerative diseases.
“The EVOS S1000 delivers a detailed snapshot of tissue microenvironments and architecture in their native state, helping researchers accelerate their experiments, achieve more with their tissue samples and drive advancements in critical research areas.”
The system’s compatibility with various reagents and antibodies ensures easy integration into existing labs, supporting the increasing demand for multiplex imaging.
Presently available in the US and Europe, the EVOS S1000 Spatial Imaging System equips researchers with the tools to advance their understanding of complex biology and develop new disease treatments.
SciLifeLab Stockholm spatial proteomics researcher and lab manager Carolina Oses Sepúlveda said: “Our lab handles everything from project design and sample preparation to imaging, and it’s critical that we deliver high-quality results to our customers, while also working to support our own research projects.
“With the new EVOS S1000, we can select and utilise any antibody or reagent, allowing us more flexibility to choose the tools that best fit our research needs, or even work without antibodies, all of which reduces sample processing time.”
In October 2024, Thermo Fisher Scientific secured the US Food and Drug Administration (FDA) approval for its Ion Torrent Oncomine Dx Target Test.
